利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

73 条记录 (耗时 0.05 秒)

    VEGF-modulated genes and methods employing them
    2.
    发明申请
    VEGF-modulated genes and methods employing them 审中-公开
    VEGF调控的基因和使用它们的方法

    公开(公告)号：US20040006780A1

    公开(公告)日：2004-01-08

    申请号：US10428487

    申请日：2003-05-02

    发明人： Hans-Peter Gerber ,  Luca Rastelli

    IPC分类号： A01K067/00 ,  A61K038/18 ,  C07K014/475 ,  C07K016/22 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： The present invention provides methods for modulating angiogenesis and/or apoptosis comprising modulating the activity of at least one VEGF-modulated gene polypeptide. The invention also provides pharmaceutical compositions for modulating angiogenesis and apoptosis for the prevention or treatment of diseases associated with VEGF-modulated genes expression. The invention also provides diagnostic assays that use VEGF-modulated gene polynucleotides that hybridize with naturally occurring sequences encoding VEGF-modulated genes and antibodies that specifically bind to the protein. The invention also provides novel human and mouse arginine-rich proteins (ARPs) and nucleotide sequences. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding ARPs and for a method for producing the protein

    摘要翻译： 本发明提供调节血管生成和/或凋亡的方法，包括调节至少一种VEGF调节的基因多肽的活性。 本发明还提供用于调节血管发生和凋亡以用于预防或治疗与VEGF调节的基因表达相关的疾病的药物组合物。 本发明还提供使用VEGF调节的基因多核苷酸的诊断测定法，其与编码VEGF调节的基因的天然存在的序列和与蛋白质特异性结合的抗体杂交。 本发明还提供新的人和小鼠富含精氨酸的蛋白质（ARP）和核苷酸序列。 本发明提供了基因工程表达载体和宿主细胞，其包含编码ARP的核酸序列和用于产生蛋白质的方法

    Immunointeractive molecules
    3.
    发明申请
    Immunointeractive molecules 审中-公开
    免疫相互作用分子

    公开(公告)号：US20040005671A1

    公开(公告)日：2004-01-08

    申请号：US10440295

    申请日：2003-05-16

    申请人： Amrad Operations Pty Ltd.

    发明人： Andrew Nash ,  Giuseppe Maccarone ,  Pierre David Scotney

    IPC分类号： C12P021/04 ,  C07K016/22

    CPC分类号： C07K14/52 ,  C07K14/71

    摘要： The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B. Accordingly, a method of screening for inhibitors of the biological activity of VEGF-B is also provided.

    摘要翻译： 本发明一般涉及免疫相互作用分子，更具体地涉及结合血管内皮生长因子-B（VEGF-B）或其功能或结构等同物并抑制VEGF-B生物学活性的抗体。 特别地，本发明涉及结合VEGF-B并抑制VEGF-B的生物学活性的去免疫化的人源化或人抗体。 这些抗体在治疗或预防与正常血管发生或血管生成或血管重构中的扰动相关的疾病中具有用途。 本发明进一步考虑了通过施用本发明的抗体调节与正常血管发生或血管发生或血管重构中的扰动有关的疾病的方法。 本发明还提供了可用于鉴定结合VEGF-B并阻断VEGF-B的生物学活性的抗体的测定系统。 因此，还提供了筛选VEGF-B生物活性抑制剂的方法。

    Specific binding agents for kshv vil-6 that neutralize a biological activity
    4.
    发明申请
    Specific binding agents for kshv vil-6 that neutralize a biological activity 失效
    用于中和生物活性的kshv vil-6的特异性结合剂

    公开(公告)号：US20030211468A1

    公开(公告)日：2003-11-13

    申请号：US10333121

    申请日：2003-01-14

    发明人： Yoshiyasu Aoki ,  Giovanna Tosato

    IPC分类号： C12Q001/70 ,  A61K039/395 ,  C07K016/22 ,  A61K048/00

    CPC分类号： G01N33/56994 ,  A61K2039/505 ,  C07K16/085 ,  C07K16/248 ,  C12Q1/705 ,  G01N33/56983 ,  G01N33/6869 ,  G01N2333/03 ,  G01N2333/5412 ,  G01N2469/10 ,  G01N2500/00 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2800/52 ,  C12Q2563/131

    摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSRV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSRV-associated disorder. The method for effectiveness the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.

    摘要翻译： 提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSRV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。 在一个实施方案中，特异性结合剂是抗体。 提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。 提供了与KSHV相关疾病的治疗方法，以及包括本发明的特异性结合剂的试剂盒。 还提供了一种用于测试试剂以治疗KSRV相关病症的有效性的方法。 具有包含vIL-6受体组分和vIL-6的无细胞系统的药剂的有效性的方法，并且比较在试剂存在下vIL-6和受体组分与vIL-6与受体组分的结合的结合 在没有代理人的情况下。 在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

    Human NHE2
    10.
    发明申请
    Human NHE2 审中-公开
    人类NHE2

    公开(公告)号：US20030096958A1

    公开(公告)日：2003-05-22

    申请号：US10218957

    申请日：2002-08-14

    申请人： Pfizer Inc.

    发明人： Scott P. Kennedy ,  Dexue Sun

    IPC分类号： C07K014/435 ,  C07K016/22 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K14/47 ,  C07K14/705

    摘要： The invention is directed to two forms of isolated or purified human NHE2 polypeptide sequences, NHE2-LF and NHE2-SF, as well as the polynucleotide coding sequences that encode the human NHE2-LF and NHE2-SF polypeptides. Also featured are NHE2-LF- and NHE2-SF-related hosts, cell membrane preparations, vectors, and antibodies, as well as methods of using cells recombinantly expressing the human NHE2-LF or NHE2-SF, to identify agents that modulate human NHE activity.

    摘要翻译： 本发明涉及两种形式的分离或纯化的人NHE2多肽序列NHE2-LF和NHE2-SF，以及编码人NHE2-LF和NHE2-SF多肽的多核苷酸编码序列。 还特征是NHE2-LF-和NHE2-SF相关宿主，细胞膜制备物，载体和抗体，以及使用重组表达人NHE2-LF或NHE2-SF的细胞的方法来鉴定调节人NHE的试剂 活动。